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 Parathyroid hormone (PTH) and vitamin 
D have been recognized as the main regula-
tors of phosphate homeostasis. 1 PTH 
accomplishes it via two opposite eff ects: it 
reduces serum phosphate by decreasing its 
renal reabsorption, and increases it either 
by directly stimulating bone turnover and 
phosphate release or by indirectly stimulat-
ing intestinal phosphate absorption 
through its stimulatory effect on renal 
1  -hydroxylase activity and 1,25(OH) 2 D 3 
(calcitriol) production. PTH binds to PTH / 
PTHrP receptor type 1 (PTHR1) in renal 
and bone cells and activates several intrac-
ellular second messengers, including Gs  -
dependent cyclic adenosine monophosphate 
(cAMP), inositol triphosphate, phospholi-
pase C, free calcium, and diacylglycerol. 1 
Some of them, namely, cAMP and phos-
pholipase C, lead to the internalization of 
the sodium – phosphate cotransporters 
NPT2a and NPT2c in proxi mal tubular 
cells, and to a fall in renal phosphate reab-
sorption. In bone cells, PTHR1s are found 
mostly in osteoblasts, and not in osteoclasts, 
which confers to PTH its anabolic action, 
increasing bone formation. However, most 
importantly physiologically, PTH stimu-
lates osteoblast RANKL (receptor activator 
of nuclear factor-  B ligand) production, 
which in turn increases osteoclast number, 
bone resorption, and subsequently phos-
phate release. 1 
 Active vitamin D, or calcitriol, results 
from a cascade of metabolic steps begin-
ning with cutaneous ultraviolet-dependent 
generation of cholecalci ferol from 7-dehy-
drocholesterol and ergosterol, followed by 
liver 25-hydroxylation of cholecalciferol, 
and lastly by renal 1  -hydroxylation of 
25(OH)D. Vitamin D metabolites are trans-
ported by the vitamin D-binding protein 
(DBP). They bind to the same receptor 
(VDR) with distinct affi  nities, thousands of 
times greater for calcitriol than for 
25(OH)D. Th e complex vitamin D / VDR 
forms nuclear heterodimers with RXR that 
interact with the vitamin D-responsive 
element on target genes to produce its 
physiological eff ects. Calcitriol increases 
renal NPT2a expression and phosphate 
reabsorption, as well as intestinal NPT2b 
expression and phosphate absorption. 
Its positive eff ect on intestinal and renal 
phosphate absorptions is counterbalanced 
by the stimulation of fibroblast growth 
factor 23 (FGF23) production. Calcitriol 
also modulates both bone resorption, 
through its differentiating effects on 
monocyte- macrophage-osteoclast cells, 
and bone  formation, through its multiple 
actions on osteoblasts. At the parathyroid 
gland, vitamin D suppresses synthesis of 
PTH by directly repressing its gene, and, 
indirectly, by increasing calcium-sensing 
receptor (CaR) expression and the sensitiv-
ity of parathyroid cells to extracellular cal-
cium. Thus, vitamin D can increase or 
decrease serum phosphate concentration 
depending on its balanced eff ect on par-
athyroid glands, bone, and intestine. 
 FGF23 is a circulating 32-kDa peptide 
secreted by osteocytes, osteoblasts, and 
osteoclasts, in response to hyperphos-
phatemia and vitamin D. 2 FGF23 reduces 
serum phosphate by two mechanisms: it 
decreases renal phosphate reabsorption 
by lowering NPT2a and NPT2c expres-
sion, and it diminishes calcitriol synthesis 
by inhibiting 1  -hydroxylase and by 
stimulating its catabolizing enzyme 24,25-
hydroxylase. The reduced calcitriol 
decreases intestinal NPT2b expression and 
phosphate absorption. FGF23 binds to and 
activates a composite receptor formed by 
the conjunction of FGF receptor 1 
(FGFR1), FGFR3, and / or FGFR4 with 
klotho. Klotho is a 130-kDa transmem-
brane protein identifi ed in 1997 in a genet-
ically created mouse strain, which displays 
hyperphosphatemia, hypercalcemia, high 
calcitriol, premature ageing, and shortened 
lifespan. 3 Klotho is expressed mainly in 
distal tubular cells, which contrasted, at 
the beginning, with the phosphaturic eff ect 
of FGF23 in proximal tubules; however, 
klotho expression is also present in proxi-
mal tubular cells. Klotho can also be shed 
from the cellular membrane by metallo-
proteases, and released into the circulation 
in a soluble form of smaller molecular 
weight with not yet fully understood 
physio logical functions. 4 
 FGF23 and klotho may regulate PTH, as 
evidenced by the expression of all players 
involved in FGF23 signaling in parathy-
roid glands, including FGFR1, FGFR3, and 
klotho. FGF23 directly decreases PTH 
mRNA expression and PTH secretion  in 
vitro as well as in  in vivo experiments. It 
may also indirectly repress the  PTH gene 
through the stimulation of parathyroid 1  -
hydroxylase activity and local production 
 Three feedback loops 
precisely regulating serum 
phosphate concentration 
 Pablo A. Ure ñ a  Torres 1 and  David P.  De Brauwere 2 
 Parathyroid hormone (PTH) and vitamin D were considered the major 
factors regulating phosphate homeostasis. Now, with the identification 
of fibroblast growth factor 23 (FGF23), a phosphaturic molecule 
inhibiting calcitriol and PTH, they need to be integrated into three 
feedback loops involving parathyroid, bone, and kidney. PTH and 
calcitriol are required for the appropriate synthesis of FGF23 by bone 
cells. PTH also regulates klotho expression in the kidney and thereby 
the phosphaturic action of FGF23. 
 Kidney International (2011)  80, 443 – 445.  doi: 10.1038/ki.2011.146 
 1 Clinique du Landy, Service de Nephrologie et 
Dialyse ,  Saint Ouen ,  France and  2 H ô pital Necker, 
Service de Biochimie ,  Paris ,  France 
 Correspondence: Pablo A. Ure ñ a Torres, Clinique 
du Landy, Service de Nephrologie et Dialyse, 
23 Rue du Landy, 93400 Saint Ouen, France.  
 E-mail:  urena.pablo@wanadoo.fr 
see original article on page 475
commentar y
444   Kidney International (2011) 80 
of calcitriol. Both eff ects depend on klotho, 
as suggested by the observations that 
reduced expression of klotho and FGFR1 
might explain the resistance of parathyroid 
cells to FGF23 in chronic kidney disease, 5 
as well as in one case of hyperphos-
phatemic familial tumoral calcinosis due 
to an inactivating  klotho mutation. 6 
Inversely, and independently of FGF23, 
klotho stimulates PTH secretion through 
the stabilization of Na / K-ATPase at the cell 
membrane. 7 However, to date, it is 
unknown whether klotho, FGF23, and 
FGFR1 interact with the CaR, the main 
regulator of PTH secretion. 
 Overexpression of FGF23 and injection 
of FGF23 into mice cause hypophos-
phatemia and reduce calcitriol; inversely, 
mice lacking FGF23 have hyperphos-
phatemia and high calcitriol. Similarly, the 
phenotype of klotho-deficient mice is 
quite similar to that of FGF23 knockout 
animals, depicting hyperphosphatemia, 
high calcitriol, and reduced lifespan, sug-
gesting that these abnormalities occur 
because FGF23 cannot act on the organs 
where klotho is normally expressed, 
namely, the kidney and para thyroid 
gland. 3 Intriguingly, most of the pheno-
type of FGF23 and klotho knockout mice 
can be rescued by a phosphate-restricted 
diet, and by disruption of vitamin D sign-
aling pathways by the silencing of either 
the VDR or the 25-hydroxyvitamin D-1  -
hydroxylase gene. Th ese fi ndings demon-
strate that the presence or the absence of 
klotho determines the tissue specifi city 
and the eff ects of FGF23. 
 L ó pez  et al. 8 (this issue) asked whether 
PTH could regulate skeletal FGF23 pro-
duction. Th ey hypothesized that if FGF23 
reduces PTH, this should lead to hypoc-
alcemia and hyperphosphatemia. Such 
hypocalcemia would be magnifi ed by low 
calcitriol and hyperphosphatemia. Th ere-
fore, there should be a mechanism pro-
tecting against the hypocalcemia in case 
of persistent high FGF23, and this mecha-
nism should block FGF23 production. 
The decreased synthesis of calcitriol 
induced by low PTH actually inhibits 
FGF23 production, but, on the other 
hand, the increase in phosphate that 
follows low PTH levels would tend to 
stimulate FGF23 synthesis. PTH might be 
necessary for FGF23 secretion, and thus 
low PTH would result in decreased 
FGF23. Th is would also help to under-
stand the contradictory action of FGF23 
on plasma phosphorus. FGF23 directly 
decreases plasma phosphate, while, indi-
rectly through decreasing PTH, it facili-
tates an increase of serum phosphate. 
 Th e authors found paradoxically low 
FGF23 levels in parathyroidectomized 
(PTX) animals in spite of hyperphos-
phatemia, suggesting that phosphate alone 
was unable to stimulate FGF23 synthesis, 
and that other factors such as PTH and / or 
calcitriol were required. Th is assumption 
should be taken with caution, since, despite 
low PTH and calcitriol, high FGF23 is seen 
in PTH-null mice and in patients with 
hypoparathyroidism. Similarly, aft er total 
parathyroidectomy, the peak of serum 
phosphate always precedes FGF23 increase 
by several days, illustrating that phosphate 
is the primary stimulus for FGF23 produc-
tion. Low PTH was probably not solely 
responsible for the low FGF23 in PTX ani-
mals. As the authors discuss, calcitriol was 
also decreased, which is probably more 
important than stimulation of FGF23 by 
PTH. Indeed, vitamin D regulates FGF23 
independently of phosphate, as suggested 
by the reduced FGF23 levels in animals 
with  VDR gene knockout selectively in 
chondrocyte cells. However, it remains to 
be investigated what would be the eff ect of 
supraphysiological doses of PTH on serum 
FGF23 levels in vitamin D-deprived ani-
mals, either by  VDR or  CYP27B1 knockout 
or by binephrectomy. It is also unknown 
how parathyroidectomy would modify the 
number and activity of bone cells produc-
ing FGF23. 
 Th e administration of physiological 
























 Figure 1  |  Regulatory mechanisms of phosphate homeostasis . From conception and throughout 
life, vertebrates need phosphate for energy, nucleic acids, cellular membrane constitution, skeletal 
formation, and a multitude of other vital functions. The only source of phosphate is external, from 
daily dietary food, which has to travel in the gut and become available for intestinal absorption, 
either actively through the cells or passively through the paracellular pathway. Once absorbed, 
inorganic phosphate enters into the extracellular compartment, particularly into the circulating 
plasma, where its concentration is tightly regulated by the three organs depicted here, parathyroid, 
bone, and kidney, interacting with one another through three feedback loops. Parathyroid glands 
produce parathyroid hormone (PTH), which, on the kidney, stimulates phosphate excretion and 
calcitriol synthesis; then, in turn, low phosphate and calcitriol directly inhibit PTH production. On 
the bone, PTH stimulates fibroblast growth factor 23 (FGF23) production and phosphate release 
following an increase in bone remodeling. FGF23 inhibits PTH secretion, but phosphate will tend to 
stimulate PTH production. FGF23, at the kidney level, stimulates urinary phosphate excretion and 
inhibits calcitriol production, tending to reduce serum phosphate levels by these two mechanisms. 
On the other hand, the renal PTH-stimulated calcitriol production stimulates FGF23 production by 
bone cells. These three counterregulatory loops maintain tightly controlled intestinal absorption 
and serum phosphate concentration. Certainly, there is now evidence that there should be an 
intestinal phosphate sensor that alerts one of these organs (the kidney), or probably more than one 
(dashed lines), in case of phosphate overload or phosphate deficiency. 
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PTX animals increased FGF23 and cal-
citriol and normalized serum phosphate 
levels. Several observations had already 
suggested that PTH could stimulate skel-
etal FGF23 production. Administration 
of (1-34)PTH to healthy individuals 
increased serum FGF23. Moreover, con-
stitutively activated PTHR1 in Jansen ’ s 
disease, which can be considered as a 
primary hyperparathyroidism with high 
PTH and hypophosphatemia, showed 
elevated FGF23. 9 Similarly, high FGF23 
is oft en seen in secondary hyperparathy-
roidism and can predict its severity and 
its resistance to vitamin D therapy 
in chronic kidney disease patients. 10 
In the same patients, serum FGF23 sig-
nifi cantly declined aft er parathyroidec-
tomy. L ó pez  et al. 8 confi rm and extend 
these previous fi ndings, demonstrating 
that PTH, either directly or indirectly via 
calcitriol, is necessary for skeletal 
FGF23 production. 
 Probably, one of the most interesting 
fi ndings of this study is the lack of eff ect 
of FGF23 on urinary and serum phos-
phate in the absence of PTH. PTX animals 
receiving physiological doses of calcitriol 
had high FGF23 but did not normalize 
serum phosphate, implying that, at least 
in the kidney, there was a key factor 
 regulated by PTH that was required for 
the phosphaturic action of FGF23. Th is 
factor was certainly klotho, as the authors 
found a reduction of klotho expression in 
the kidneys of PTX animals. Importantly, 
renal klotho expression was restored to 
normal levels aft er PTH supplementation, 
allowing FGF23 to exert its phosphaturic 
action and the normalization of serum 
phosphate levels. 
 In summary, the study by L ó pez  et al. 8 
shows that PTH is necessary in main-
taining normal circulating FGF23 levels, 
that changes in calcitriol levels unques-
tionably play a role in the stimulatory 
eff ect of PTH on FGF23, and that PTH 
regulates klotho expression in the kidney 
and thereby the phosphaturic eff ect of 
FGF23. It confi rms the existence of three 
feedback loops, involving parathyroid 
glands, bone, and kidney, regulating 
serum phosphate concentration ( Figure 
1 ) and opens a number of areas for clin-
ical and experimental research in the 
fi eld of phosphate homeostasis. 
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 Since 1883, when Ringer discovered 
that a trace amount of Ca 2  +   from tap 
water was suffi  cient to induce contrac-
tion of a frog ’ s heart, the role of Ca 2  +   in 
regulating physiological functions has 
been continually investigated. We now 
know that appropriate concentrations 
of extracellular and intracellular Ca 2  +  
are vital to the survival of all organisms 
from the simplest unicellular organism 
to mammals and that highly regulated 
processes are required to provide con-
stant and appropriate quantities of the 
ion to cells and tissues. Therefore, 
sophisticated mechanisms enable cells 
to detect minor changes in extracellular 
Ca 2  +   content to counteract and modify 
their behavior accordingly. 
 In major organisms, Ca 2  +   has to be 
controlled both systemically and locally, 
and in mammals, the control of systemic 
calcium homeostasis is mediated by the 
calcium-sensing receptor (CaSR). 
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 Calcium sensing in podocytes 
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 Besides its primary function in maintaining systemic calcium 
homeostasis, the calcium-sensing receptor (CaSR) is expressed by many 
cell types, with different, sometimes opposite, regulatory functions. 
Novel work from Oh and collaborators shows that activation of CaSR 
in podocytes has prosurvival effects and protects the cell from 
puromycin aminonucleoside damage. Given that the cellular 
consequences of CaSR activation are largely context-dependent, 
further studies will be required to elucidate its precise role in podocyte 
physiology and pathophysiology. 
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